PC
COGT icon

Pier Capital’s Cogent Biosciences COGT Stock Holding History

Pier Capital’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.9M Buy
101,304
+55,044
+119% +$2.03M 0.64% 76
2025
Q4 		$1.64M Buy
+46,260
New +$1.3M 0.26% 96

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Pier Capital's COGT Position: Q1 2026 in Review

Pier Capital increased its Cogent Biosciences (COGT) stake by 119% in Q1 2026, buying an estimated $2.03M and bringing the position to 101,304 shares worth $3.9M. The position accounts for 0.64% of the portfolio, ranked #76.

Pier Capital first reported a position in COGT in Q4 2025 and has held it in 2 quarters since. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Pier Capital held 101,304 shares of Cogent Biosciences worth $3.9M as of Q1 2026.
  • Pier Capital bought 55,044 Cogent Biosciences shares in Q1 2026, an estimated $2.03M.
  • Cogent Biosciences made up 0.64% of Pier Capital's portfolio in Q1 2026, its #76 holding.
  • Pier Capital first reported a position in Cogent Biosciences in Q4 2025 and has held it in 2 quarters since.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Pier Capital's 13F filing for Q1 2026, filed 14 May 2026.